Physiologically based pharmacokinetic modeling of ponatinib to describe drug –drug interactions in patients with cancer

ConclusionsThe PBPK model predicted a significant drug interaction when ponatinib was combined with a strong CYP3A4 inducer. Conversely, the combination with weak-to-strong CYP3A4 inhibitors did not suggest a drug interaction with ponatinib.

Source: Cancer Chemotherapy and Pharmacology - August 23, 2022 Category: Cancer & Oncology Source Type: research